

Anke-Peggy Holtorf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4616252/publications.pdf>

Version: 2024-02-01

38
papers

753
citations

623734

14
h-index

526287

27
g-index

40
all docs

40
docs citations

40
times ranked

840
citing authors

#	ARTICLE	IF	CITATIONS
1	Pilot approach to analyzing patient and citizen involvement in health technology assessment in four diverse low- and middle-income countries. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e1.	0.5	3
2	Case studies for implementing MCDA for tender and purchasing decisions in hospitals in Indonesia and Thailand. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 52.	2.4	2
3	Making patient blood management the new norm(al) as experienced by implementors in diverse countries. <i>BMC Health Services Research</i> , 2021, 21, 634.	2.2	18
4	Weighing Price and Performance for Decisions for Multisource Pharmaceutical Bidding in Public Hospitals in Thailand. , 2020, , .		4
5	Value-Based Evaluation of Chinese Provincial Health Insurance Policy Schemes. , 2020, , .		2
6	Barriers and facilitators of exploiting the potential of value-added medicines. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 229-236.	1.4	7
7	Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group. <i>Value in Health</i> , 2020, 23, 529-539.	0.3	59
8	External Reference Pricing for Pharmaceuticalsâ€”A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage. <i>Value in Health Regional Issues</i> , 2019, 19, 122-131.	1.2	25
9	Stakeholder driven development of a multi-criteria decision analysis tool for purchasing off-patent pharmaceuticals in Kuwait. <i>Journal of Pharmaceutical Policy and Practice</i> , 2019, 12, 9.	2.4	12
10	Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient Needs. <i>Frontiers in Medicine</i> , 2019, 6, 82.	2.6	31
11	OP24 Sensitizing Researchers And Developers For Patient Needs And Value. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 10-11.	0.5	0
12	Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 591-607.	2.1	22
13	Health economic assessment of Gd-EOB-DTPA MRI versus ECCM-MRI and multi-detector CT for diagnosis of hepatocellular carcinoma in China. <i>PLoS ONE</i> , 2018, 13, e0191095.	2.5	11
14	The Role of Patients inMarket Access. , 2018, , 267-288.		3
15	Market Access in Germany. , 2018, , 21-40.		0
16	Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status. <i>BMC Health Services Research</i> , 2017, 17, 371.	2.2	17
17	EVALUATION OF PATIENT AND PUBLIC INVOLVEMENT INITIATIVES IN HEALTH TECHNOLOGY ASSESSMENT: A SURVEY OF INTERNATIONAL AGENCIES. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 715-723.	0.5	31
18	OP110 Survey Of Health Technology Assessment Evaluation Strategies For Patient And Public Involvement. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 51-52.	0.5	0

#	ARTICLE	IF	CITATIONS
19	Health economic evaluation of Gd-EOB-DTPA MRI vs ECCM-MRI and multi-detector computed tomography in patients with suspected hepatocellular carcinoma in Thailand and South Korea. <i>Journal of Medical Economics</i> , 2016, 19, 759-768.	2.1	14
20	Moving Center Stage: patients claim their role in healthcare. <i>Farmeconomia E Percorsi Terapeutici</i> , 2016, 17, 3-6.	0.1	0
21	Need for Multicriteria Evaluation of Generic Drug Policies. <i>Value in Health</i> , 2015, 18, 346-351.	0.3	35
22	Are Patient Reported Outcomes Relevant To Patients? Learnings From A Patient Advocate Survey. <i>Value in Health</i> , 2014, 17, A517.	0.3	0
23	PHP142 Drug Shortages Around the World and the Underlying Reasons. <i>Value in Health</i> , 2012, 15, A314.	0.3	1
24	PMD28 Comparing the Cost and Diagnostic Efficiency of Gadoteric Acid-Enhanced MRI Versus Extracellular Contrast Media-Enhanced MRI and Multidetector Computed Tomography in Patients With Suspected Hepatocellular Carcinoma in Thailand and Korea. <i>Value in Health</i> , 2012, 15, A349-A350.	0.3	1
25	PMD33 The Impact of Three Different Imaging Strategies on Surgery Planning for Patients With Colorectal Cancer Liver Metastases. <i>Value in Health</i> , 2012, 15, A350-A351.	0.3	0
26	Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. <i>Value in Health</i> , 2012, 15, 1162-1171.	0.3	119
27	Implementing CER: What Will It Take?. <i>Journal of Managed Care Pharmacy</i> , 2012, 18, S19-S29.	2.2	6
28	Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets. <i>American Health and Drug Benefits</i> , 2012, 5, 428-38.	0.5	7
29	Standardizing Quality Assessment of Observational Studies for Decision Making in Health Care. <i>Journal of Managed Care Pharmacy</i> , 2009, 15, 275-283.	2.2	17
30	Systematic review on quality control for drug management programs: Is quality reported in the literature?. <i>BMC Health Services Research</i> , 2009, 9, 38.	2.2	6
31	Incorporating Observational Data into the Formulary Decision-Making Process—Summary of a Roundtable Discussion. <i>Journal of Managed Care Pharmacy</i> , 2008, 14, 302-308.	2.2	8
32	Development of optimized transfectoma cell lines for production of chimeric antibodies in hollow fiber cell culture systems. <i>Biotechnology and Bioengineering</i> , 1995, 45, 310-319.	3.3	12
33	Variation in N-linked carbohydrate chains in different batches of two chimeric monoclonal IgG1 antibodies produced by different murine SP2/0 transfectoma cell subclones. <i>Glycoconjugate Journal</i> , 1995, 12, 318-330.	2.7	22
34	Diurnal Changes in Sensitivity to Melatonin in Intact and Pinealectomized Djungarian Hamsters: Effects on Thermogenesis, Cold Tolerance, and Gonads. <i>Journal of Pineal Research</i> , 1985, 2, 393-403.	7.4	30
35	Effects of Injections and/or Chronic Implants of Melatonin and 5-Methoxytryptamine on Plasma Thyroid Hormones in Male and Female Syrian Hamsters. <i>Neuroendocrinology</i> , 1984, 39, 361-366.	2.5	23
36	Relative Efficacy of Melatonin and 5-Methoxytryptamine in Terms of Their Antigonadotrophic and Counterantigonadotrophic Actions in Male Syrian Hamsters. <i>Journal of Pineal Research</i> , 1984, 1, 91-98.	7.4	11

#	ARTICLE	IF	CITATIONS
37	Concurrent determination of enzymatic activities and substrate concentrations in the melatonin synthetic pathway within the same rat pineal gland. <i>Journal of Neuroscience Research</i> , 1984, 11, 59-66.	2.9	174
38	The influence of different light irradiances on pineal N-acetyltransferase activity and melatonin levels in the cotton rat, <i>Sigmodon hispidus</i> . <i>Life Sciences</i> , 1983, 33, 1543-1547.	4.3	17